by The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market is estimated to be valued at US$ 2,980 Mn in 2027 and is expected to exhibit a CAGR of 31.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening condition characterized by the buildup of abnormal deposits of misfolded transthyretin protein (TTR) in the heart. Symptoms usually include shortness of breath, fatigue, leg swelling and unexplained weight loss. Currently available treatment options include medications to reduce amyloid deposits, heart and kidney transplant, and devices to assist heart function.
Market Dynamics:
The transthyretin amyloid cardiomyopathy treatment market is driven by the increasing prevalence of cardiomyopathy disorders and approval of novel therapies. As per the latest research published in the European Journal of Heart Failure, the prevalence rate of ATTR-CM is 13 per 100,000 in people over the age of 60. Moreover, several pharmaceutical companies are engaged in developing novel therapies for treatment of ATTR-CM. For instance, in 2019, the U.S FDA approved Pfizer’s Vyndaqel (Tafamidis) capsules and Janssen Pharmaceutical’s Inossimod for treatment of ATTR-CM. Such approval of novel drugs is expected to boost the market growth during the forecast period.
Key Takeaways
The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size is expected to witness high growth, exhibiting CAGR of 31.1% over the forecast period, due to increasing prevalence of ATTR-CM and robust product pipeline.
Market size: The global ATTR-CM treatment market was valued at US$ 748.80 million in 2020 and is anticipated to reach US$ 13,181.31 million by 2027 driven by approval and launch of novel therapies such as Onpattro, Vyndaqel and Inotersen.
Regional analysis: North America currently dominates the global market and is expected to maintain its lead over the forecast period owing to growing diagnosis rate and availability of advanced treatment options in the US. Europe is poised to exhibit substantial growth owing to increasing research collaborations.
Key players: Key players operating in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market are Pfizer Inc., GlaxoSmithKline Plc., Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
